Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2016-002550-20 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Klinikum Ludwigsburg | OTHER |
| Helios Klinikum Krefeld | UNKNOWN |
| Charite University, Berlin, Germany | OTHER |
| Assign International, Berlin, Germany |
Not provided
Not provided
Not provided
Not provided
The investigators will perform a multicenter, 2:1 randomized, double-blinded, placebo-controlled trial of AMR in patients with diarrhea predominant-IBS (IBS-D) diagnosed according to Rome III criteria and the IBS-QOL questionnaire. Central supply and quality control of donor material will be used to control bias.
Primary endpoint is improvement of IBS-SSS (Severity Score System) compared to baseline. Secondary endpoints include changes in IBS-QOL, short term safety and one year follow up to control long term effects, safety and changes in and acceptance of donor microbiome after AMR using16S rDNA sequencing and quantitative diversity analysis.
This study assesses allogeneic microbiota reconstitution (AMR) as novel treatment to improve symptoms and quality of life of patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
The investigators will perform a prospective multicenter, 2:1 randomized, double-blinded, placebo-controlled trial of AMR in patients with IBS-D diagnosed according to Rome III criteria and the IBS-QOL questionnaire.
The experimental intervention is an infusion of donor feces via gastroscopy. The placebo intervention is an infusion of sterile saline via gastroscopy.
Planned number of patients included in the study: 42 patients Planned per-protocol group: 33 patients
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Verum-AMR | Experimental | Patients receiving Verum-Allogeneic Microbiota Reconstitution via gastroscopy |
|
| Placebo-AMR | Placebo Comparator | Patients receiving Placebo(Saline)-Infusion via gastroscopy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Allogeneic microbiota reconstitution | Procedure | gastroscopic microbiota Infusion (Verum) |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Decrease of the IBS-SSS questionnaire > 105 Points compared to baseline | 90 days after intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Improvement of IBS-QOL using IBS-QOL-questionnaire compared to baseline | 90 days and 1 year after intervention | |
| Changes and acceptance of donor microbiome (16S rDNA-analysis) | 16S rDNA-analysis for microbiome biodiversity, correlation to IBS-Symptom Severity Score (IBS-SSS) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Thomas TW Seufferlein, Prof. Dr. | University Hospital Ulm | Principal Investigator |
| Martin Wagner, Prof. Dr. | University Hospital Ulm | Study Director |
| Thomas Frieling, Prof. Dr. | Helios Klinikum Krefeld | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Helios Klinikum Krefeld | Krefeld | Germany | ||||
| Ulm University Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 2783214 | Background | Borody TJ, George L, Andrews P, Brandl S, Noonan S, Cole P, Hyland L, Morgan A, Maysey J, Moore-Jones D. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust. 1989 May 15;150(10):604. doi: 10.5694/j.1326-5377.1989.tb136704.x. No abstract available. | |
| 22339879 | Background |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| UNKNOWN |
Not provided
Not provided
Not provided
Not provided
| Placebo-Allogeneic microbiota reconstitution |
| Procedure |
gastroscopic saline Infusion (placebo) |
|
| 90 days after intervention |
| Number of participants with treatment related adverse events | follow-up 1 year |
| Ulm |
| Germany |
| Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2012 Jun;24(6):521-30, e248. doi: 10.1111/j.1365-2982.2012.01891.x. Epub 2012 Feb 20. |
| 23433203 | Background | Crouzet L, Gaultier E, Del'Homme C, Cartier C, Delmas E, Dapoigny M, Fioramonti J, Bernalier-Donadille A. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil. 2013 Apr;25(4):e272-82. doi: 10.1111/nmo.12103. Epub 2013 Feb 25. |
| 12030961 | Background | El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther. 2002 Jun;16(6):1171-85. doi: 10.1046/j.1365-2036.2002.01290.x. |
| 21298604 | Background | Frieling T, Meis K, Kolck UW, Homann J, Hulsdonk A, Haars U, Hertfelder HJ, Oldenburg J, Seidel H, Molderings GJ. Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome. Z Gastroenterol. 2011 Feb;49(2):191-4. doi: 10.1055/s-0029-1245707. Epub 2011 Feb 4. |
| 20716985 | Background | Grehan MJ, Borody TJ, Leis SM, Campbell J, Mitchell H, Wettstein A. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol. 2010 Sep;44(8):551-61. doi: 10.1097/MCG.0b013e3181e5d06b. |
| 23333862 | Background | Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes. 2013 Mar-Apr;4(2):125-35. doi: 10.4161/gmic.23571. Epub 2013 Jan 18. |
| 17919270 | Background | Kajander K, Myllyluoma E, Rajilic-Stojanovic M, Kyronpalo S, Rasmussen M, Jarvenpaa S, Zoetendal EG, de Vos WM, Vapaatalo H, Korpela R. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 2008 Jan 1;27(1):48-57. doi: 10.1111/j.1365-2036.2007.03542.x. Epub 2007 Oct 5. |
| 23380084 | Background | Kashyap PC, Marcobal A, Ursell LK, Larauche M, Duboc H, Earle KA, Sonnenburg ED, Ferreyra JA, Higginbottom SK, Million M, Tache Y, Pasricha PJ, Knight R, Farrugia G, Sonnenburg JL. Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice. Gastroenterology. 2013 May;144(5):967-77. doi: 10.1053/j.gastro.2013.01.047. Epub 2013 Feb 1. |
| 21391171 | Background | Keller J, Wedel T, Seidl H, Kreis ME, Andresen V, Preiss JC, Layer P, van der Voort I. [S3 guideline of the German Society for Digestive and Metabolic Diseases (DGVS) and the German Society for Neurogastroenterology and Motility (DGNM) to the definition, pathophysiology, diagnosis and treatment of intestinal motility]. Z Gastroenterol. 2011 Mar;49(3):374-90. doi: 10.1055/s-0029-1245993. Epub 2011 Mar 9. No abstract available. German. |
| 16678561 | Background | Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006 Apr;130(5):1480-91. doi: 10.1053/j.gastro.2005.11.061. |
| 22426087 | Background | Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4. doi: 10.1016/j.cgh.2012.02.029. Epub 2012 Mar 15. |
| 20101257 | Background | Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010 Mar;7(3):163-73. doi: 10.1038/nrgastro.2010.4. Epub 2010 Jan 26. |
| 22070725 | Background | Parkes GC, Rayment NB, Hudspith BN, Petrovska L, Lomer MC, Brostoff J, Whelan K, Sanderson JD. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil. 2012 Jan;24(1):31-9. doi: 10.1111/j.1365-2982.2011.01803.x. Epub 2011 Nov 9. |
| 23286720 | Background | Rajilic-Stojanovic M, Heilig HG, Tims S, Zoetendal EG, de Vos WM. Long-term monitoring of the human intestinal microbiota composition. Environ Microbiol. 2012 Oct 15. doi: 10.1111/1462-2920.12023. Online ahead of print. |
| 22730468 | Background | Simren M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013 Jan;62(1):159-76. doi: 10.1136/gutjnl-2012-302167. Epub 2012 Jun 22. |
| 19457422 | Background | Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009 May;136(6):1979-88. doi: 10.1053/j.gastro.2009.02.074. Epub 2009 May 7. |
| 23323867 | Background | van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16. |
| 23829297 | Background | Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, Seo JG. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014 Jan;29(1):52-9. doi: 10.1111/jgh.12322. |
| 25322359 | Background | Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014 Nov 5;312(17):1772-8. doi: 10.1001/jama.2014.13875. |
| 16802539 | Background | Frieling T. [Functional and inflammatory bowel disorders]. Med Klin (Munich). 2006 Mar 22;101 Suppl 1:139-42. German. |
| 23468820 | Background | Kleger A, Schnell J, Essig A, Wagner M, Bommer M, Seufferlein T, Harter G. Fecal transplant in refractory Clostridium difficile colitis. Dtsch Arztebl Int. 2013 Feb;110(7):108-15. doi: 10.3238/arztebl.2013.0108. Epub 2013 Feb 15. |